[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity
Insider Trade Summary
Net Seller: 60,000 shares ($3,387,517)
Net Sell
12 txns
Insider
Torley Helen
Role
PRESIDENT AND CEO
Sold
60,000 shs ($3.39M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 4,254 | $56.742 | $241K |
| Sale | Common Stock | 15,746 | $57.617 | $907K |
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 19,792 | $56.426 | $1.12M |
| Sale | Common Stock | 208 | $57.076 | $12K |
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 3,598 | $54.483 | $196K |
| Sale | Common Stock | 16,402 | $55.738 | $914K |
Holdings After Transaction:
Option to Purchase Common Stock — 256,569 shares (Direct);
Common Stock — 753,719 shares (Direct)
Footnotes (1)
- The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Represents a weighted average sales price per share. The shares were sold at prices ranging from $54.17 to $55.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.17 to $56.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.055 to $57.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.05 to $57.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.184 to $57.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.185 to $57.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.
AI-generated analysis. How Rhea-AI works. Not financial advice.
